– Data results participated across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics’ uninterrupted commitment to advancing aesthetic drug
– Analyses of 15 times ofpost-marketing surveillance data demonstrate the global reported rate of delayed- onset nodes associated with dermal paddings on the Vycross technology platform is low(<0.016).
– Results from 3 clinical studies showcasing a customizable platform with patent- pending LTN Complex, to address the appearance of facial hyperpigmentation in a wide range of demographic populations
–Dr. DiAnne Davis to bandy the new Forces of Beauty ® Report from the DREAM( Driving ethnical Equity in Aesthetic Medicine) Initiative ® and at Diversity, Equity and Addition( DEI) event
Allergan Aesthetics, an AbbVie company,( NYSE ABBV) blazoned moment that eight scientific objectifications from its leading portfolio of aesthetic products and treatments will be presented at the American Society for Dermatologic Surgery( ASDS) meeting taking place October 6- 10 in Denver.
Allergan Aesthetics has one of the largest, most- delved portfolio and channel in the medical aesthetics assiduity. Data presented across a broad diapason of aesthetic suggestions aims to further scientific exploration and ameliorate patient issues.
” Our scientific excellence continues to help drive advancements in aesthetic drug, as well bring poignant treatments to our guests and cases encyclopedically,” said Darin Messina, Senior Vice President, Allergan Aesthetics R&D.” The data presented at ASDS reinforces our leadership in aesthetics and also the commitment of our exploration and development platoon to drive invention for the assiduity and share literacy with the broader medical community.”
At the meeting, experimenters will spotlight globalpost-marketing surveillance data on the reported rates of delayed- onset nodes presenting four or further weeks after injection of hyaluronic acid paddings grounded on the Vycross technology platform. The analyses of 15 times of data demonstrate the global reported rate of delayed- onset nodes associated with dermal paddings on the Vycross technology platform is low(<0.016). seditious nodes, which generally bear intervention/ treatment, were reported less constantly thannon-inflammatory nodes.
also,Dr. DiAnne Davis, a board- certified ornamental dermatologist out of Dallas, Texas, will bandy the new Forces of Beauty ® Report from Allergan Aesthetics’ DREAM( Driving ethnical Equity in Aesthetic Medicine) Initiative ® at the Diversity, Equity and Addition( DEI) event on Friday, October 7. The report provides a new understanding of what inclusive and representative beauty looks like moment by slipping light on how hardly defined Eurocentric ideals continue to impact women of color. By surveying over,000 women aged 21- 65, from multiple geographic locales and backgrounds, the report explores what defines beauty, how beauty impacts women’s lives, and the interplay between beauty and race
Key abstracts are outlined below. Complete abstracts and details on presentation dates and times can be found on the ASDS website.
| Abstract Title | Presentation Details |
| Facial | |
| Hyaluronic Acid Filler VYC-25L for Jawline Restoration Yields High Satisfaction, Improved Jawline Measurements, and Sustained Effect Across Age, Gender, and Skin Types for up to 12 Months | Virtual Presentation |
| Delayed-onset Nodules Following Vycross Hyaluronic Acid Filler Injections: Reported Rates From Global Post-marketing Surveillance | Virtual Presentation |
| Body Contouring | |
| A Prospective, Open-Label Study to Evaluate Functional Changes Following Electromagnetic Muscle Stimulation of Abdominal Muscle | Virtual Presentation |
| Multi-Country Study to Evaluate Patient Satisfaction with a Dual Applicator Cryolipolysis System for Non-Invasive Fat Reduction in Abdomen, Flanks, Upper Arms, Inner Thighs, Outer Thighs, and Submental Area (Study Design) | Virtual Presentation |
| Mechanism for Improvement in the Appearance of Skin Laxity Resulting from a Single Treatment With Acoustic Subcision: Induction of New Collagen (Type III) and Elastin | Virtual Presentation |
| Skincare | |
| Efficacy and Tolerability of Novel Topical Pigment-Correcting Serums With Biweekly Diamond Tip Microdermabrasion Treatments on Facial Hyperpigmentation (HP), Including Melasma and Post-inflammatory HP | Virtual Presentation |
| Efficacy of Novel Multimodality Pigment-Correcting Serum for Moderate to Severe Facial Hyperpigmentation, Including Melasma, in a 12-Week, Split-Face, Double-blind, Randomized Controlled Trial | Virtual Presentation |
| Efficacy of a Targeted Pigment-Correcting Spot Treatment Cream for Solar Lentigines and Post-inflammatory Hyperpigmentation in a 12-Week, Single-Center Clinical Study | Virtual Presentation |
IMPORTANT SAFETY INFORMATION & APPROVED USES
JUVÉDERM ® Collection of Fillers Important Information
suggestions
JUVÉDERM ® VOLUMA ® XC injectable gel is indicated for deep( subcutaneous and/ or supraperiosteal) injection for impertinence addition to correct age- related volume deficiency in themid-face and for addition of the chin region to ameliorate the chin profile in grown-ups over the age of 21.
JUVÉDERM ® VOLUX ™ XC injectable gel is indicated for subcutaneous and/ or supraperiosteal injection for enhancement of jawline description in grown-ups over the age of 21 with moderate to severe loss of jawline description.
JUVÉDERM ® VOLLURE ® XC injectable gel is indicated for injection into themid-to-deep dermis for correction of moderate to severe facial wrinkles and crowds( similar as nasolabial crowds) in grown-ups over the age of 21.
JUVÉDERM ® VOLBELLA ® XC injectable gel is indicated for injection into the lips for lip addition and correction of perioral rhytids, and for the enhancement of infraorbital hollowing in grown-ups over the age of 21.
JUVÉDERM ® Ultra Plus XC and JUVÉDERM ® Ultra XC injectable gels are indicated for injection into themid-to-deep dermis for correction of moderate to severe facial wrinkles and crowds( similar as nasolabial crowds).
JUVÉDERM ® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip addition in grown-ups over the age of 21.
About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company, develops, manufactures, and requests a portfolio of leading aesthetics brands and products. Their aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Their thing is to constantly give guests worldwide with invention, education, exceptional service, and a commitment to excellence, all with a particular touch.
Source link:https://news.abbvie.com/
